Sequoia Financial Advisors LLC Purchases 130 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Sequoia Financial Advisors LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 18.0% in the 4th quarter, HoldingsChannel reports. The fund owned 853 shares of the biotechnology company’s stock after buying an additional 130 shares during the period. Sequoia Financial Advisors LLC’s holdings in United Therapeutics were worth $301,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its holdings in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after acquiring an additional 33 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after buying an additional 39 shares during the last quarter. MBM Wealth Consultants LLC boosted its position in shares of United Therapeutics by 1.9% during the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 41 shares during the last quarter. UMB Bank n.a. boosted its position in shares of United Therapeutics by 4.9% during the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 51 shares during the last quarter. Finally, Access Investment Management LLC boosted its position in shares of United Therapeutics by 0.8% during the fourth quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock valued at $2,588,000 after buying an additional 55 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on UTHR shares. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $318.85 on Thursday. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The business’s fifty day moving average price is $347.20 and its 200-day moving average price is $357.65. The stock has a market capitalization of $14.32 billion, a PE ratio of 14.00, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 EPS. As a group, equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,255 shares of company stock worth $32,614,521. 11.90% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.